Overview

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Status:
Completed
Trial end date:
2020-06-19
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan